Medulloblastoma and ependymoma account for about 30% of all newly diagnosed brain tumours in children. As curative treatment options are available since many years, our attention has to focus on late effects in survivors of brain tumours. Neurocognitive sequelae are of concern and more rarely development of secondary tumours.
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We report on a 37-year-old patient who was treated 23 years earlier for a large supratentorial right temporooccipital ependymoma (8 · 7 · 5 cm). This ependymoma was cured with gross-total resection, involved field radiation (54Gy, conventional fractionation) and maintenance chemotherapy (VM-26 and CCNU) for 1 year. After a latency period of more than 20 years an undifferentiated sarcoma with a high proliferation-index ( Figure 1a , b) developed in the previously irradiated field involving skull and scalp (Figure 2a) . A complete remission of this secondary malignant tumour could be obtained by subtotal surgery followed by seven cycles of epirubicin and ifosfamide (Figure 2b ). Our patient experiences good quality of life, 18 months after diagnosis of his secondary tumour. He runs his own toyshop, is able to drive a car and has normal social contacts. Neuropsychological assessment after his last treatment revealed left sided neglect and minor learning deficits for visual patterns. 
